The Highbridge Capital Management LLC Invests $107000 in Ocular Therapeutix, Inc. (OCUL)

Hedge funds and other institutional investors own 65.25% of the company's stock.

Investors who are keeping close eye on Ocular Therapeutix, Inc. Morgan Stanley's target price would indicate a potential upside of 25.39% from the stock's previous close. These shares are worth $355,605 and were traded at $7.85 each. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) earned "Equal-Weight" rating by Morgan Stanley on Friday, July 14. It has underperformed by 26.20% the S&P500. Compton Capital Management Inc bought 2,963 shares as the company's stock rose 10.88% with the market. Berson & Corrado Investment Advisors LLC now owns 32,805 shares of the biopharmaceutical company's stock valued at $304,000 after buying an additional 1,785 shares during the last quarter.

Market Capitalization can be thought of as the overall price to buy the company. The stock declined 0.07% or $0.11 reaching $162.75 on the news. Deltec Asset Management LLC boosted its stake in shares of Ocular Therapeutix by 247.1% in the first quarter.

Some buy side analysts are also providing their Analysis on Ocular Therapeutix, Inc., where 0 analysts have rated the stock as Strong buy, 3 analysts have given a Buy signal, 2 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. BTIG Research downgraded shares of Ocular Therapeutix from a buy rating to a neutral rating in a research note on Monday, May 15th. The firm has "Buy" rating by Cantor Fitzgerald given on Monday, July 10. The firm has "Overweight" rating by Cantor Fitzgerald given on Wednesday, July 12.

Morgan Stanley reiterated their equal weight rating on shares of Ocular Therapeutix, Inc. The company rocked its 52-Week High of $11.907 and touched its 52-Week Low of $4.04.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Friday, May 5th. (NASDAQ:OCUL) remains a cheap stock. INVESTOR ALERT: "Wolf Haldenstein Adler ..." with publication date: "July 12, 2017. Ocular Therapeutix, Inc. (NASDAQ:OCUL) notched a 12-month high of $28.50 while $60.00 target is by far the most aggressive out of analysts who are now evaluating OCUL, $31.5 higher than the next highest 52-week price estimate. The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.51 million. It now has negative earnings.

Let's take a gaze at how the stock has been performing recently.

Zacks offers analysts with an Average Broker Rating (or ABR), basing it on sell-side recommendations. Therefore 94% are positive. The firm has "Overweight" rating by Morgan Stanley given on Thursday, February 18. The rating was maintained by Morgan Stanley with "Overweight" on Thursday, April 28. SunTrust has "Buy" rating and $135 target. A rating of 3 would signify a consensus Hold recommendation. And the values below 20 that it is oversold indicate prices could very well bounce upwards. (NASDAQ:OCUL) during the first quarter, according to its most recent disclosure with the SEC.

Investors sentiment decreased to 1.25 in Q4 2016. Whittier Trust holds 0.2% in Facebook Inc (NASDAQ:FB) or 41,078 shares. 15,400 are held by Arrowpoint Asset Mgmt. A stock with a small float will generally be more volatile than a stock with a large float, apart from having limited liquidity and wider bid-ask spread. Jump Trading Lc stated it has 0.04% in Facebook Inc (NASDAQ:FB). The insider now directly owns 112,060 shares worth $709,340. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. Iconiq Ltd Company invested 0.07% of its portfolio in Facebook Inc (NASDAQ:FB).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.